Cardiomyopathy and kidney function in agalsidase beta ‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis

ConclusionsCardiac hypertrophy, progressing during pretreatment follow ‐up, appeared to stabilize during sustained agalsidase beta treatment. eGFR decline remained within normal ranges. This suggests that treatment may prevent further Fabry‐related progression of cardiomyopathy in female patients and maintain normal kidney function.

Source: ESC Heart Failure - February 27, 2020 Category: Cardiology Authors: Christoph Wanner, Ulla Feldt ‐Rasmussen, Ana Jovanovic, Aleš Linhart, Meng Yang, Elvira Ponce, Eva Brand, Dominique P. Germain, Derralynn A. Hughes, John L. Jefferies, Ana Maria Martins, Albina Nowak, Bojan Vujkovac, Frank Weidemann, Mich Tags: Original Research Article Source Type: research